eCite Digital Repository
Effects of perhexiline on myocardial deformation in patients with ischaemic left ventricular dysfunction
Citation
Bansal, M and Chan, J and Leano, R and Pillans, P and Horowitz, J and Marwick, TH, Effects of perhexiline on myocardial deformation in patients with ischaemic left ventricular dysfunction, International Journal of Cardiology, 139, (2) pp. 107-112. ISSN 0167-5273 (2010) [Refereed Article]
Copyright Statement
Copyright 2010 Elsevier Ireland
DOI: doi:10.1016/j.ijcard.2009.08.007
Abstract
Background
Perhexiline improves functional capacity in heart failure, but the mechanisms are undefined. We sought its effects on myocardial deformation in patients with viable myocardium.
Methods Thirty-six medically-treated patients, stable at least 6 months post-infarction with LV dysfunction and myocardial viability shown by dobutamine echo (DbE) were randomised to receive perhexiline or matching placebo for 1 year. Cardiopulmonary exercise testing and DbE were performed at baseline and follow-up. Peak-systolic strain (S) and strain rate (SR) were measured offline in 111 dysfunctional segments in the placebo and 88 in the treatment group at rest, low-dose (LDD) and peak-dose dobutamine (PDD).
Results The serum perhexiline level was 0.27 ± 0.7 µg/l. There was no difference in the wall motion response to dobutamine at baseline and follow-up. Resting strain and SR were similar in the two groups at baseline and follow-up. However, SR at LDD and PDD increased in the placebo group and worsened during the same period in the perhexiline group. Patients on perhexiline and placebo had a similar rate-pressure product and exercise duration at baseline (7.9 ± 2.7 vs 8.7 ± 3.3 min, p = NS) and follow-up (9.6 ± 4.6 vs 10.1 ± 3.03 min, p = NS).
Conclusion Perhexiline does not improve the deformation of abnormal myocardial segments in patients with ischaemic LV dysfunction.
Methods Thirty-six medically-treated patients, stable at least 6 months post-infarction with LV dysfunction and myocardial viability shown by dobutamine echo (DbE) were randomised to receive perhexiline or matching placebo for 1 year. Cardiopulmonary exercise testing and DbE were performed at baseline and follow-up. Peak-systolic strain (S) and strain rate (SR) were measured offline in 111 dysfunctional segments in the placebo and 88 in the treatment group at rest, low-dose (LDD) and peak-dose dobutamine (PDD).
Results The serum perhexiline level was 0.27 ± 0.7 µg/l. There was no difference in the wall motion response to dobutamine at baseline and follow-up. Resting strain and SR were similar in the two groups at baseline and follow-up. However, SR at LDD and PDD increased in the placebo group and worsened during the same period in the perhexiline group. Patients on perhexiline and placebo had a similar rate-pressure product and exercise duration at baseline (7.9 ± 2.7 vs 8.7 ± 3.3 min, p = NS) and follow-up (9.6 ± 4.6 vs 10.1 ± 3.03 min, p = NS).
Conclusion Perhexiline does not improve the deformation of abnormal myocardial segments in patients with ischaemic LV dysfunction.
Item Details
| Item Type: | Refereed Article |
|---|---|
| Research Division: | Biomedical and Clinical Sciences |
| Research Group: | Cardiovascular medicine and haematology |
| Research Field: | Cardiology (incl. cardiovascular diseases) |
| Objective Division: | Health |
| Objective Group: | Clinical health |
| Objective Field: | Clinical health not elsewhere classified |
| UTAS Author: | Marwick, TH (Professor Tom Marwick) |
| ID Code: | 90878 |
| Year Published: | 2010 |
| Web of Science® Times Cited: | 6 |
| Deposited By: | Menzies Institute for Medical Research |
| Deposited On: | 2014-04-30 |
| Last Modified: | 2014-05-01 |
| Downloads: | 0 |
Repository Staff Only: item control page